亚洲在线日韩伦理片,96精品国产AⅤ一区二区,青鸟影视网,yy黄色频道,国内精品久久久精品AV电影院

深圳微芯生物科技股份有限公司 Shenzhen Chipscreen Biosciences Co. Ltd.

Latest News

Chipscreen Biosciences' Brain-Penetrant Aurora B Selective Inhibitor CS231295 Tablet Receives FDA IND Approval, Advancing Global Clinical Development

 SHENZHEN, China, July 31, 2025 /PRNewswire/ -- Shenzhen Chipscreen Biosciences Co., Ltd. ("Chipscre...

2025-07-31 17:55 1868

The clinical trial application for first-line treatment of extensive disease small cell lung cancer with Chiauranib has been approved

 SHENZHEN, China, Nov. 1, 2024 /PRNewswire/ -- On November?1, Shenzhen Chipscreen Biosciences Co., ...

2024-11-01 19:04 2950

Chipscreen Biosciences' Innovative Anti-Tumor Drug CS231295 Tablets: Investigational New Drug (IND) Application Accepted

 SHENZHEN, China, Oct. 17, 2024 /PRNewswire/ --?On October 17, 2024, Shenzhen Chipscreen Biosciences...

2024-10-17 21:38 2107

Chiglitazar for the Treatment of MASH Phase II Clinical Study Selected for Oral Presentation at the 2024 American Liver Disease Annual Meeting

 SHENZHEN, China, Oct. 15, 2024 /PRNewswire/ -- On October 15, 2024, the list of selected candidates...

2024-10-15 22:08 2042

Treatment of Type 2 diabetes with Chiglitazar combined with Metformin Approved for listing by the National Medical Products Administration

 SHENZHEN, China, July 19, 2024 /PRNewswire/ -- On July 19,?Shenzhen Chipscreen Biosciences Co., Ltd...

2024-07-19 22:01 5265

National Medical Products Administration (NMPA) Approves Chipscreen Bioscience's Chidamide (Epidaza) combined with R-CHOP for the treatment of diffuse large B-cell lymphoma

 SHENZHEN, China, April 30, 2024 /PRNewswire/ -- Shenzhen Chipscreen Biosciences Co., Ltd. (Chipscre...

2024-04-30 20:55 2145

Positive results from Phase II clinical trial (CGZ203 study) of Chiglitazar monotherapy for non-alcoholic steatohepatitis

 SHENZHEN, China, March 18, 2024 /PRNewswire/ -- On March 18 2024, Shenzhen chipscreen biosciences C...

2024-03-18 19:25 2143

Chipscreen NewWay: First Patient Dosed in Phase 1 Trial of the Bispecific Antibody NWY001, a Next-generation Tumor Immunotherapy in Patients with Advanced Solid Tumors

 CHENGDU, China, Jan. 16, 2024 /PRNewswire/ -- Chengdu Chipscreen NewWay Biosciences Co., Ltd. (NewW...

2024-01-16 17:00 2269

Chipscreen's New Drug Candidate CS32582 Capsules Approved for Clinical Treatment of Psoriasis

 SHENZHEN, China, Nov. 2, 2023 /PRNewswire/ -- On Oct. 31, 2023,?Shenzhen Chipscreen Biosciences Co....

2023-11-02 15:58 1856

Licensing Partner of Shenzhen Chipscreen Biosciences - HUYABIO International, Receives Regulatory Approval for Chidamide Monotherapy of Peripheral T-Cell Lymphoma(PTCL) in Japan

 SHENZHEN, China, Dec. 1, 2021 /PRNewswire/ --?Shenzhen Chipscreen Biosciences' licensing partner, H...

2021-12-01 21:54 2318

Licensing Partner of Shenzhen Chipscreen Biosciences - HUYABIO International, Receives Regulatory Approval for Chidamide Monotherapy of Adult T-cell Leukemia/lymphoma in Japan

 SHENZHEN, China, June 24, 2021 /PRNewswire/ --?Shenzhen Chipscreen Biosciences' licensing partner, ...

2021-06-24 19:00 3151

Chipscreen received a Phase 1b/2 clinical trial of Chiauranib/CS2164 IND clearance from the US Food and Drug Administration (FDA)

 SHENZHEN,?China, April 16, 2021 /PRNewswire/ --?Shenzhen Chipscreen Biosciences , aChina headquarter...

2021-04-16 18:24 2574

Chiauranib, an Anti-tumor Drug Developed by Chipscreen, is Given CDE "Breakthrough Therapy Designation"

 SHENZHEN, China, Jan. 5, 2021 /RPNewswire/ -- Last December 25, the anti-tumor drug candidate Chiau...

2021-01-05 17:49 2854

Chipscreen and HISUN reach a strategic cooperation

 SHENZHEN, China, Dec. 16, 2020 /PRNewswire/ -- On December 16, 2020, SHENZHEN CHIPSCREEN BIOSCIENC...

2020-12-16 17:59 3662